Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Expectations By $0.45 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) announced its quarterly earnings data on Monday. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45), Zacks reports. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals updated its FY 2025 guidance to EPS.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded up $9.38 during trading hours on Thursday, reaching $462.58. The company had a trading volume of 1,349,470 shares, compared to its average volume of 1,569,901. The firm has a market cap of $119.13 billion, a PE ratio of -232.45, a price-to-earnings-growth ratio of 1.80 and a beta of 0.41. The business has a fifty day moving average price of $435.70 and a 200-day moving average price of $461.79. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the sale, the executive vice president now directly owns 64,021 shares of the company's stock, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on VRTX. Piper Sandler dropped their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. StockNews.com lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 21st. JPMorgan Chase & Co. lowered their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday. Finally, BMO Capital Markets lowered their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a research report on Friday, December 20th. Ten equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $505.96.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.